The case for prostate-specific antigen screening starting at age 40

Cancer

Volumn 113, Issue 6, 2008, Pages 1278-1281

  Nadler, Robert B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; EDITORIAL; HUMAN; INCIDENCE; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

ADULT; AGE FACTORS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 53149141740     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23721     Document Type: Editorial

References (22)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MI): National Cancer Institute; 2007.
2. American Cancer Society. Cancer Facts and Figures. Available at: www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. (1997-2007). Accessed April 29, 2008.
3. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52:8-22.
4. National Comprehensive Cancer Network. Prostate Cancer Early Detection. Practice Guidelines in Oncology. Available at: www.nccn.org/professionals/ physician_gls/PDF/prostate_detection.pdf. Accessed July 11, 2007.
5. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67:316-320.
6. Loeb S, Roehl KA, Catalona WJ, Nadler RB. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age? BJU Int. 101:817-821, 2008 Apr.
7. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172(4 pt 1):1297-1301.
8. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostatic specific antigen levels. J Urol. 1995;154:407-413.
9. Nadler RB, McNaughton Collins M, Propert KJ, et al. Chronic Prostatitis Collaborative Research Network. Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urol. 2006;67:337-342.
10. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351: 125-135.
11. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521-1527.
12. Loeb S, Roehl KA, Catalona WJ, Nadler RB. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol. 2007; 177:899-902.
13. Kundu SD, Grubb RL, Roehl KA, Antenor JA, Han M, Catalona WJ. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2ng/mL. J Urol. 2005;173:1116-1120.
14. Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ. Comparison of prostatic specific antigen velocity in screened versus referred patients with prostate cancer. J Urol. 2008;179:1340-1343.
15. Potts JM. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol. 2000:164:1550-1553.
16. Krumholtz JS, Carvalhal GF, Ramos CG, et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urol. 2002:60:469-473; discussion, 473-474.
17. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer amount men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;27;350:2239-2246
18. Erratum in: N Engl J Med. 2004; 351:1470.
19. Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. JUrol. 2007;177:499-504.
20. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lowerrisk prostate cancer in the United States. J Nat Can Inst. 2006;98:1134-1141.
21. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer prediction, detection and monitoring. Nat Rev Cancer. 2008:8:268-278.
22. Erratum in: Nat Rev Cancer. 2008;8:403.